Next Article in Journal
Modulating TRPV4 Channel Activity in Pro-Inflammatory Macrophages within the 3D Tissue Analog
Previous Article in Journal
A Bioactive Gelatin-Methacrylate Incorporating Magnesium Phosphate Cement for Bone Regeneration
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive

by
Jacek Wilczyński
1,*,
Edyta Paradowska
2 and
Miłosz Wilczyński
3,4
1
Department of Gynecological Surgery and Gynecological Oncology, Medical University of Lodz, 4 Kosciuszki Str., 90-419 Lodz, Poland
2
Laboratory of Virology, Institute of Medical Biology of the Polish Academy of Sciences, 106 Lodowa Str., 93-232 Lodz, Poland
3
Department of Surgical, Endoscopic and Gynecological Oncology, Polish Mother’s Health Center—Research Institute, 281/289 Rzgowska Str., 93-338 Lodz, Poland
4
Department of Surgical and Endoscopic Gynecology, Medical University of Lodz, 4 Kosciuszki Str., 90-419 Lodz, Poland
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(1), 229; https://doi.org/10.3390/biomedicines12010229
Submission received: 12 November 2023 / Revised: 14 January 2024 / Accepted: 17 January 2024 / Published: 19 January 2024
(This article belongs to the Section Cancer Biology and Oncology)

Abstract

High-grade serous ovarian cancer (HGSOC) is the most lethal tumor of the female genital tract. Despite extensive studies and the identification of some precursor lesions like serous tubal intraepithelial cancer (STIC) or the deviated mutational status of the patients (BRCA germinal mutation), the pathophysiology of HGSOC and the existence of particular risk factors is still a puzzle. Moreover, a lack of screening programs results in delayed diagnosis, which is accompanied by a secondary chemo-resistance of the tumor and usually results in a high recurrence rate after the primary therapy. Therefore, there is an urgent need to identify the substantial risk factors for both predisposed and low-risk populations of women, as well as to create an economically and clinically justified screening program. This paper reviews the classic and novel risk factors for HGSOC and methods of diagnosis and prediction, including serum biomarkers, the liquid biopsy of circulating tumor cells or circulating tumor DNA, epigenetic markers, exosomes, and genomic and proteomic biomarkers. The novel future complex approach to ovarian cancer diagnosis should be devised based on these findings, and the general outcome of such an approach is proposed and discussed in the paper.
Keywords: ovarian cancer; risk factors; diagnosis; prediction; biomarkers; liquid biopsy; circulating tumor cells; circulating tumor DNA ovarian cancer; risk factors; diagnosis; prediction; biomarkers; liquid biopsy; circulating tumor cells; circulating tumor DNA

Share and Cite

MDPI and ACS Style

Wilczyński, J.; Paradowska, E.; Wilczyński, M. High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive. Biomedicines 2024, 12, 229. https://doi.org/10.3390/biomedicines12010229

AMA Style

Wilczyński J, Paradowska E, Wilczyński M. High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive. Biomedicines. 2024; 12(1):229. https://doi.org/10.3390/biomedicines12010229

Chicago/Turabian Style

Wilczyński, Jacek, Edyta Paradowska, and Miłosz Wilczyński. 2024. "High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive" Biomedicines 12, no. 1: 229. https://doi.org/10.3390/biomedicines12010229

APA Style

Wilczyński, J., Paradowska, E., & Wilczyński, M. (2024). High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive. Biomedicines, 12(1), 229. https://doi.org/10.3390/biomedicines12010229

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop